Logo image of IPH.PA

INNATE PHARMA SA (IPH.PA) Stock Overview

Europe - EPA:IPH - FR0010331421 - Common Stock

1.58 EUR
-0.09 (-5.16%)
Last: 9/19/2025, 7:00:00 PM

IPH.PA Key Statistics, Chart & Performance

Key Statistics
52 Week High2.5
52 Week Low1.33
Market Cap145.62M
Shares92.17M
Float64.67M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.61
PEN/A
Fwd PE4.32
Earnings (Next)09-17 2025-09-17/bmo
IPO10-31 2006-10-31
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


IPH.PA short term performance overview.The bars show the price performance of IPH.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

IPH.PA long term performance overview.The bars show the price performance of IPH.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of IPH.PA is 1.58 EUR. In the past month the price decreased by -21.39%. In the past year, price decreased by -19.88%.

INNATE PHARMA SA / IPH Daily stock chart

IPH.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.12 334.23B
AMG.DE AMGEN INC 13.04 129.50B
GIS.DE GILEAD SCIENCES INC 14.74 119.81B
1VRTX.MI VERTEX PHARMACEUTICALS INC 23.36 85.81B
VX1.DE VERTEX PHARMACEUTICALS INC 22.91 84.19B
1AE.DE ARGENX SE 85.58 38.29B
ARGX.BR ARGENX SE 85.53 38.26B
22UA.DE BIONTECH SE-ADR N/A 19.75B
1BIIB.MI BIOGEN INC 9.34 18.55B
IDP.DE BIOGEN INC 8.96 17.79B
1EXEL.MI EXELIXIS INC 18.85 8.93B
0QF.DE MODERNA INC N/A 8.33B

About IPH.PA

Company Profile

IPH logo image Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.

Company Info

INNATE PHARMA SA

117 avenue de Luminy, Bp 30191

Marseille PACA FR

Employees: 181

IPH Company Website

IPH Investor Relations

Phone: 33430303030

INNATE PHARMA SA / IPH.PA FAQ

What is the stock price of INNATE PHARMA SA today?

The current stock price of IPH.PA is 1.58 EUR. The price decreased by -5.16% in the last trading session.


What is the ticker symbol for INNATE PHARMA SA stock?

The exchange symbol of INNATE PHARMA SA is IPH and it is listed on the Euronext Paris - Matif exchange.


On which exchange is IPH.PA stock listed?

IPH.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for INNATE PHARMA SA stock?

8 analysts have analysed IPH.PA and the average price target is 5.64 EUR. This implies a price increase of 257% is expected in the next year compared to the current price of 1.58. Check the INNATE PHARMA SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INNATE PHARMA SA worth?

INNATE PHARMA SA (IPH.PA) has a market capitalization of 145.62M EUR. This makes IPH.PA a Micro Cap stock.


How many employees does INNATE PHARMA SA have?

INNATE PHARMA SA (IPH.PA) currently has 181 employees.


What are the support and resistance levels for INNATE PHARMA SA (IPH.PA) stock?

INNATE PHARMA SA (IPH.PA) has a support level at 1.53 and a resistance level at 1.77. Check the full technical report for a detailed analysis of IPH.PA support and resistance levels.


Is INNATE PHARMA SA (IPH.PA) expected to grow?

The Revenue of INNATE PHARMA SA (IPH.PA) is expected to grow by 172.13% in the next year. Check the estimates tab for more information on the IPH.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INNATE PHARMA SA (IPH.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INNATE PHARMA SA (IPH.PA) stock pay dividends?

IPH.PA does not pay a dividend.


When does INNATE PHARMA SA (IPH.PA) report earnings?

INNATE PHARMA SA (IPH.PA) will report earnings on 2025-09-17, before the market open.


What is the Price/Earnings (PE) ratio of INNATE PHARMA SA (IPH.PA)?

INNATE PHARMA SA (IPH.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).


IPH.PA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to IPH.PA. When comparing the yearly performance of all stocks, IPH.PA is a bad performer in the overall market: 88.87% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IPH.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IPH.PA. IPH.PA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IPH.PA Financial Highlights

Over the last trailing twelve months IPH.PA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -549.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -44.54%
ROE -560.01%
Debt/Equity 8.02
Chartmill High Growth Momentum
EPS Q2Q%-163.49%
Sales Q2Q%-73.85%
EPS 1Y (TTM)-549.63%
Revenue 1Y (TTM)-75.68%

IPH.PA Forecast & Estimates

8 analysts have analysed IPH.PA and the average price target is 5.64 EUR. This implies a price increase of 257% is expected in the next year compared to the current price of 1.58.

For the next year, analysts expect an EPS growth of 189.51% and a revenue growth 172.13% for IPH.PA


Analysts
Analysts77.5
Price Target5.64 (256.96%)
EPS Next Y189.51%
Revenue Next Year172.13%

IPH.PA Ownership

Ownership
Inst Owners10.09%
Ins Owners2.18%
Short Float %N/A
Short RatioN/A